KEY POINTS Chronic rhinosinusitis refers to symptomatic inflammation of the nose and paranasal sinuses that has been present for a minimum of 3 months.[1][1] Its true prevalence is difficult to ...

Learn how Aimovig for migraine works, how well it works, what to know before starting, and its possible side effects. Experts and community members also weigh in about their experiences with Aimovig.

JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025(Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodi ...

About PEMGARDA PEMGARDA™ (pemivibart) is a half-life extended investigational monoclonal antibody (mAb). PEMGARDA was engineered from adintrevimab ... PEMGARDA is not authorized for use for treatment ...

We demonstrate here that administration of a CD154-specific monoclonal ... antibody against CD154 is a promising agent for clinical use in human allotransplantation. Here, we found that treatment ...

Methods: In the present study, to identify human neutralizing monoclonal antibody (mAb) against JEV or/and ZIKV ... performed in strict accordance with the animal welfare act and public health service ...

Then, the recombinant A29 protein was used as an antigen to immunize BALB/c mice, and a total of 4 monoclonal antibodies ... sensitivity and specificity. In the future, improvements can be made to the ...

(MENAFN- JCN NewsWire) FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the treatment ... monoclonal antibody in the setting of focal neurologic symptoms of ARIA and the use of ...

Genetic variants and clinical factors affecting the response to 5-fluorouracil–based treatment in Chilean patients with advanced colorectal cancer. Sex differences in toxicities and survival outcomes ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment ... monoclonal antibody in the setting of focal neurologic symptoms of ARIA and the use ...